ABC signs an agreement with GDLST

ABC Cambridge has entered into a strategic agreement with Global Detian Life Sciences Technology (GDLST) Ltd, a Beijing-based biotechnology partner that will enable the joint development and manufacture of novel oncology therapeutics with design and production anchored in China. This collaboration aligns with the rapidly evolving Chinese biopharmaceutical ecosystem, where innovative drug discovery and clinical development activities are expanding in both scale and regulatory openness to international partnerships — China’s National Medical Products Administration recently approved numerous domestically developed innovative drugs and the country has been actively integrating into the global biopharmaceutical innovation system. Under the terms of the agreement, ABC Cambridge will leverage GDLST’s R&D and manufacturing infrastructure in China to accelerate the discovery, optimisation and eventual production of new cancer drug candidates targeted at high-unmet-need indications, while benefiting from China’s growing life sciences market and regulatory framework that supports foreign involvement in drug development and manufacturing. This partnership not only expands ABC Cambridge’s international footprint but also positions it to contribute meaningfully to the global oncology drug pipeline through access to China’s research talent, clinical trial networks and manufacturing capacity.